by Barry101 | Aug 4, 2017 | Press Release
Cytokine Signatures Could Lead to the First Empirical Measure of Disease Severity in Chronic Fatigue SyndromePHILADELPHIA, Aug. 04, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) said today that a new study led by a team of researchers from Stanford University may...
by Barry101 | Jul 10, 2017 | Press Release
12 Pancreatic Cancer Patients Receiving Ampligen® Immuno-Oncology Therapy in Early Access ProgramPHILADELPHIA, July 10, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) announced that 12 pancreatic patients are currently undergoing treatment with single-agent...
by Barry101 | May 31, 2017 | Press Release
Joseph C. Horvath, M.D., Named Deputy Chief Medical Officer to Oversee Ampligen European Pancreatic Cancer Programs PHILADELPHIA, May 31, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that it...
by Barry101 | May 31, 2017 | Press Release
Promotes Carol Smith, Ph.D., to Chief Manufacturing Officer and Deputy Chief Scientific OfficerPHILADELPHIA, May 31, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that it continues to build its...
by Barry101 | May 15, 2017 | Press Release
The company has generated revenues from the lots of newly manufactured AmpligenPHILADELPHIA, May 15, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2017. The net loss was approximately $2,821,000...
by Barry101 | Mar 31, 2017 | Press Release
Hemispherx Biopharma Management Team Continues Its Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder ValueConference Call Scheduled for Friday, April 7th at 11:00 AM EDTPHILADELPHIA, March 31,...
